> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# SIGA Waits For U.S. Orders After A Quarter Without Product Sales
- URL: https://www.bullished.co/siga-waits-for-u-s-orders-after-a-quarter-without-product-sales-a621e7ad/
- Published: 2026-11-09T22:17:06.000Z
- Updated: 2026-11-09T22:17:06.000Z
- Description: Canada's repeat order offers future deliveries, while additional FDA laboratory work pushes a prevention application target to 2028.
- Author: Matteo Parrino
- Tags: Earnings, SIGA, Industry: Healthcare

SIGA Technologies, which sells the smallpox antiviral TPOXX to governments, recorded no third-quarter product sales while awaiting a replacement U.S. purchasing contract, management said on Monday's earnings call. Chief Executive Officer Diem Nguyen said stakeholder discussions still left her expecting an award, but preparedness support "does not always translate into predictable procurement."

## U.S. Purchases Outlast The Commitments

SIGA completed its remaining U.S. product deliveries in the second quarter. Management had already told investors on the previous call that securing another contract was taking longer than in the past.

An analyst asked whether U.S. midterm election results could alter biodefense funding or procurement timing. Nguyen cited historical bipartisan support and said, "we don't currently expect a change in direction regarding congressional funding for biodefense." She also said management did not expect a material effect on the contract process beyond the usual election transition.

Chief Financial Officer Daniel Luckshire put product revenue for the first nine months at approximately $42 million, mostly recorded in the second quarter. That included approximately $26 million of intravenous TPOXX delivered to the U.S. Strategic National Stockpile and approximately $13 million sold to two international customers; customers included governments in Asia Pacific and Europe.

Research and development revenue totaled approximately $7 million for the nine months, including approximately $1 million in the third quarter. Nine-month operating income was approximately $2 million, excluding interest and taxes, against a third-quarter operating loss of approximately $7 million. Net income was approximately $6 million for the nine months, or $0.09 per diluted share; the quarter's net loss was approximately $3 million, or $0.04 per diluted share.

SIGA ended September with approximately $116 million in cash and no debt. Its market value was $223 million as of Monday at 5:11 p.m. ET.

## Canada's Orders Start In 2027

Canada's Department of National Defense signed an [October supply contract](https://www.globenewswire.com/news-release/2026/11/09/3398911/0/en/siga-reports-financial-results-for-three-and-nine-months-ended-september-30-2026.html?ref=bullished.co) worth up to approximately $15 million over five years. About $9 million represents firm purchases during the first three years; up to $6 million consists of optional purchases.

Luckshire confirmed that Canada was the opportunity discussed on the previous call. Another international contract remains in advanced negotiations.

Management expects Canadian deliveries to begin in 2027, with equal quantities in each of the first three fiscal years. Canada's April-to-March fiscal calendar could put two deliveries in one calendar year. The military can exercise options for delivery throughout the five-year contract.

Canada's earlier agreement, awarded in April 2020 for up to approximately $14 million, was completed in 2025\. SIGA supplies oral TPOXX domestically and internationally and an intravenous version to the U.S. government, relying on outside manufacturers to produce and package its medicines.

Nguyen said European preparedness has historically emphasized vaccines. SIGA is pursuing discussions about adding antivirals to national and regional stockpiles. She said the European label change can require additional discussion and affect timing, but does not change management's view of the long-term smallpox opportunity; SIGA recently renewed its smallpox treatment filings in Europe and the UK.

## Prevention Application Moves To 2028

SIGA now expects to submit its FDA application for post-exposure smallpox prevention in 2028\. Nguyen said the agency requested additional validation and laboratory work ahead of sample analysis planned by the CDC. SIGA continues working with the Department of War, FDA and CDC on the program.

Management still expects early-stage pediatric formulation study results by year-end. If successful, Nguyen said, that formulation alongside the oral and intravenous versions would cover patients from infancy through adulthood.

Chief Scientific Officer Dennis Hruby [retired Monday](https://finance.yahoo.com/healthcare/articles/siga-announces-retirement-chief-scientific-210100889.html?ref=bullished.co) and will remain an adviser. He joined SIGA in 1996, when no smallpox treatment was approved. TPOXX now has approvals in the U.S., Canada, the European Union, the UK and Japan, and has been sold to more than 30 countries.

Canada's firm purchases provide a delivery schedule beginning in 2027\. The replacement U.S. contract remains an expectation rather than an awarded order.

Learn

- [How To Read An Earnings Call Transcript: Start With Guidance, Then Find What's Missing →](https://www.bullished.co/learn/how-to-read-an-earnings-call/)  
How to read an earnings call transcript: check guidance first, look for dropped metrics, compare growth with last quarter, and watch hedged wording.

### Sources

- [SIGA Announces Retirement of Chief Scientific Officer Dennis Hruby, Ph.D.](https://finance.yahoo.com/healthcare/articles/siga-announces-retirement-chief-scientific-210100889.html?ref=bullished.co) — Yahoo Finance
- [SIGA Reports Financial Results for Three and Nine Months](https://www.globenewswire.com/news-release/2026/11/09/3398911/0/en/siga-reports-financial-results-for-three-and-nine-months-ended-september-30-2026.html?ref=bullished.co) — globenewswire.com
- [SIGA Announces Retirement of Chief Scientific Officer](https://www.globenewswire.com/news-release/2026/11/09/3398916/0/en/siga-announces-retirement-of-chief-scientific-officer-dennis-hruby-ph-d.html?ref=bullished.co) — globenewswire.com